Lexeo Therapeutics to Present Interim Phase 1/2 Data on LX1001 at CTAD 2024

Lexeo Therapeutics, Inc., a clinical-stage genetic medicine company, has announced that it will present interim data from its Phase 1/2 clinical trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid from October 29 to November 1, 2024. The data presentation will highlight the safety and efficacy of LX1001 across four different dose cohorts.

LX1001 is an AAVrh10-based gene therapy candidate designed to introduce the protective APOE2 gene into the central nervous systems of patients with APOE4-associated Alzheimer’s disease. This gene therapy aims to offer a new treatment option for APOE4 homozygotes, who currently have limited effective treatments available.

Dr. Sandi See Tai, Chief Development Officer of Lexeo Therapeutics, emphasized the significance of the trial, noting that APOE4-associated Alzheimer’s disease is a particularly challenging condition with few effective treatments. The presentation at the CTAD conference will share new safety and biomarker data from four dose cohorts of LX1001. The Phase 1/2 trial is an open-label study designed to assess the safety and tolerability of LX1001 in fifteen patients who have Alzheimer’s disease and are homozygous for the APOE4 allele. The study concluded its patient enrollment in the fourth quarter of 2023.

The data to be presented will include 12-month results for the first three cohorts and 6-month results for the fourth cohort, focusing on safety and multiple efficacy measures such as protein expression and tau and amyloid biomarkers. This information will be presented at the CTAD conference on October 30, 2024, at 10:50 AM CET.

LX1001 has the potential to express the APOE2 gene in the central nervous system of APOE4 homozygous patients, which could slow or halt the progression of Alzheimer’s disease. This therapy has received Fast Track designation from the FDA, which could expedite its development and review process.

Lexeo Therapeutics, based in New York City, is committed to advancing the treatment of genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease through innovative genetic medicine approaches. The company leverages early proof-of-concept data to drive its pipeline of cardiovascular and Alzheimer’s disease programs, aiming to transform healthcare with pioneering science.

In summary, the upcoming presentation at the CTAD conference will provide an important update on the safety and preliminary efficacy of LX1001 in treating APOE4-associated Alzheimer’s disease. This interim data could mark a significant step forward in addressing the genetic underpinnings of this challenging condition, offering hope for better treatment options in the future.